Glaucoma

Detailed Overview

POAG is a chronic, insidious disease. The eye's drainage system (trabecular meshwork) gradually becomes less efficient, causing aqueous humor to build up and increase intraocular pressure. This mechanical stress, combined with vascular insufficiency, damages the delicate nerve fibers at the optic disc. Because it initially affects the mid-peripheral visual field, the brain easily compensates, and patients are entirely asymptomatic until late in the disease. It is a leading cause of irreversible blindness globally.

Epidemiology & Demographics

Affects over 60 million people worldwide. Prevalence increases significantly with age. African Americans and Hispanics have a 3-4 times higher risk of developing POAG and suffer from more aggressive disease compared to Caucasians.

Etiological Mechanism

The exact cause of ganglion cell death is multifactorial, primarily involving mechanical compression due to elevated IOP and decreased optic nerve perfusion. In POAG, the anterior chamber angle is open, but there is microscopic resistance to aqueous outflow in the trabecular meshwork.

Primary Causes

Increased resistance in the Trabecular Meshwork

Genetic Predisposition (e.g., MYOC mutations)

Vascular dysregulation

• Elevated Intraocular Pressure: The only modifiable risk factor. IOP > 21 mmHg is highly suspicious.
• Advanced Age: Risk increases steadily for those over 60.
• Race: African and Hispanic descent are high risk.
• Family History: First-degree relative with glaucoma increases risk up to 9-fold.
• Thin Central Corneal Thickness (CCT): Causes artificial underestimation of true IOP and is an independent risk factor.

Aqueous humor is produced by the ciliary body, flows through the pupil, and drains via the trabecular meshwork into Schlemm's canal. In POAG, glycosaminoglycan accumulation and endothelial dysfunction in the trabecular meshwork increase resistance to outflow. The resulting rise in IOP applies mechanical pressure to the lamina cribrosa at the optic nerve head. This impedes axonal transport in retinal ganglion cells and compromises microvascular perfusion. Apoptosis of ganglion cells ensues, leading to enlargement of the optic cup (cupping) and corresponding visual field deficits.

Characteristic Clinical Presentation

• Asymptomatic Early: Often called the 'sneak thief of sight', as early stages have no symptoms.
• Peripheral Vision Loss: Slow, progressive loss of side vision, often going unnoticed.
• Tunnel Vision: In advanced stages, only central vision remains.
• Bumping into objects: Noticeable clumsiness due to loss of spatial awareness and peripheral field.

Physical Examination Signs

• Elevated Intraocular Pressure (usually >21 mmHg, measured by Goldmann applanation).
• Optic Disc Cupping (Cup-to-Disc ratio > 0.5, or asymmetry > 0.2 between eyes).
• Notching of the optic nerve rim (especially inferiorly or superiorly).
• Disc Hemorrhage (Drance hemorrhage crossing the disc margin).

• Irreversible Blindness: Total loss of vision if the optic nerve is completely destroyed.
• Loss of Driving Privileges: Due to insufficient peripheral visual field.

Diagnostic Criteria & Guidelines

Diagnosis requires demonstrating characteristic optic nerve damage (via dilated fundus exam and OCT showing retinal nerve fiber layer thinning) AND corresponding visual field defects (via automated perimetry). Gonioscopy is required to confirm the angle is open.

Differential Diagnosis

• Ocular Hypertension (High IOP but NO nerve damage or field loss).
• Secondary Glaucomas (Pigmentary, Pseudoexfoliative, Neovascular).
• Acute Angle-Closure Glaucoma (Presents with sudden severe pain and red eye).
• Compressive Optic Neuropathy (e.g., Pituitary tumor).

Laboratory Tests & Biomarkers

• None: Glaucoma is diagnosed clinically and via ophthalmic imaging, not blood tests.

Imaging Modalities & Findings

• Optical Coherence Tomography (OCT):
• Humphrey Visual Field (HVF):

• Mild
  Optic nerve abnormalities present, but visual field testing is normal.
• Moderate
  Optic nerve abnormalities with visual field defects in one hemifield, not within 5 degrees of fixation.
• Severe
  Visual field defects in both hemifields or within 5 degrees of central fixation.

Second-Line & Adjunctive Therapy

Topical Beta-Blockers (e.g., Timolol 0.5% BID) - decreases aqueous production; contraindicated in asthma/COPD. Alpha-2 Agonists (Brimonidine 0.2% TID). Carbonic Anhydrase Inhibitors (Dorzolamide 2% TID). Often used in combination if target IOP is not met.

Surgical & Procedural Management

Minimally Invasive Glaucoma Surgery (MIGS) such as iStent, often done concurrently with cataract surgery. For advanced/refractory cases: Trabeculectomy (creating a fistula for fluid to drain under the conjunctiva) or Glaucoma Drainage Devices (Tube shunts).

Recommended Lifestyle Changes

• Strict adherence to daily eye drop regimen; consistency is key to preventing blindness.
• Aerobic exercise can modestly lower IOP, but avoid inverted yoga positions or heavy weightlifting which can spike IOP.
• Inform providers of glaucoma, as systemic steroids can drastically increase eye pressure.

Patient Counseling & Advice

Emphasize that treatments cannot restore lost vision, only preserve what is left. Therefore, they must use their eye drops every day for the rest of their lives, even though their eyes 'feel fine'. Warn about Latanoprost side effects (iris color darkening, eyelash growth).

Follow-Up & Monitoring Schedule

Patients require life-long monitoring. IOP checks every 3-6 months. Visual fields and OCT imaging performed every 6-12 months to monitor for disease progression. If progression is noted, the 'Target IOP' must be lowered further.

Preventive Strategies

Comprehensive dilated eye exams every 1-2 years for individuals over 40 (especially African Americans and those with family history) to catch the disease in the asymptomatic stage.

With early diagnosis and strict adherence to treatment, the vast majority of patients retain useful vision for their lifetime. Untreated, it invariably progresses to total blindness.